Table 1.
The deubiquitination substrates and downstream signaling pathways of USP10 in different cancer types.
| Cancer types | Deubiquitination substrates | Downstream signaling pathways |
|---|---|---|
| Lung cancer | PTEN, MSH2, p53, p14ARF, HDAC, | AKT/mTOR |
| Hepatocellular carcinoma | Smad4, GASAL1, PCNA, YAP/TAZ, AMPKα, PTEN | TGF-β, AKT/mTOR |
| Acute myeloid leukemia | FLT3, SYK | / |
| Ovarian cancer | p14ARF, G3BP1 | / |
| Prostate cancer | P53, G3BP2, EGFR | Androgen receptor signaling, MKK4/JNK/Bax, MEK1/2/ERK/cyclinD1 |
| Breast cancer | p53, Top2α | / |
| Gastric carcinoma | p53 | / |
| Small intestinal adenocarcinoma | Synergistic with p14ARF, TP53 | / |
| Colorectal cancer | NLRP7, SIRT6, p53, MSI2 | NF-κB |
| Pancreatic cancer | YAP1 | / |
| Esophageal carcinoma | PCNA | / |
| Chronic myeloid leukemia | SKP2, | Bcr-Abl |
| Glioblastoma | CCND1 | / |
| Thyroid cancer | p53 |
USP10, Ubiquitin-specific peptidase 10; PTEN, phosphatase and tensin homologue on chromosome 10; MSH2, MutS homolog 2; p14ARF, p14 alternate reading frame; HDAC, histone deacetylase; GASAL1, growth arrest associated lncRNA 1; PCNA, proliferating cell nuclear antigen; YAP/TAZ, yes-associated protein/transcriptional coactivator with PDZ-binding motif; AMPKα, AMP-activated protein kinase α; FLT3, FMS-like tyrosine kinase 3; SYK, spleen tyrosine kinase; G3BP1, GTPase-activating protein-binding protein 1; G3BP2, GTPase-activating protein-binding protein 2; EGFR, epidermal growth factor receptor; TOP2α, topoisomerase IIα; TP53, tumor protein p53; NLRP7, NACHT, LRR, and PYD domain-containing protein 7; SIRT6, sirtuin 6; MSI2, musashi 2; YAP1, yes-associated protein 1; SKP2, S-phase kinase-associated protein 2; CCND1, Cyclin D1.